血浆ctDNA分析检测晚期非小细胞肺癌患者EGFR T790M突变
研究评估血浆cobas EGFR突变检测v2在既往EGFR酪氨酸激酶抑制剂治疗后进展的晚期非小细胞肺癌患者中检测T790M突变的性能,以确定奥希替尼治疗资格。551例配对肿瘤组织和血浆样本中,血浆与组织检测T790M的阳性百分比一致性和阴性百分比一致性分别为61%和79%。血浆与二代测序比较的阳性和阴性百分比一致性均达90%以上。组织和血浆检测均T790M阳性的可评估患者中,奥希替尼客观缓解率为64%(95%CI 57-70)。
要点
- 血浆cobas检测在组织T790M阳性患者中检出T790M的阳性百分比一致性为61%。
- 血浆cobas检测与二代测序比较的阳性和阴性百分比一致性均达90%以上。
- 组织和血浆均T790M阳性的可评估患者中,奥希替尼客观缓解率为64%(95%CI 57-70)。
核心结论
- 血浆cobas检测在61%的组织T790M突变阳性患者中检出T790M突变。
- 为降低血浆假阴性结果风险,血浆检测阴性的患者在可行时应进行组织检测。
研究设计与样本
- 研究对AURA extension和AURA2 II期研究筛选患者的配对肿瘤组织和血浆样本进行cobas EGFR突变检测。
- 以cobas组织检测和二代测序方法(MiSeq)为参考评估血浆检测性能。
- 筛选期间共551例患者提供配对肿瘤组织和血浆样本。
- 通过盲法独立中心审查评估血浆T790M突变阳性并接受奥希替尼治疗患者的客观缓解率。
主要发现
- 血浆cobas检测与组织检测检测T790M突变的合并阳性百分比一致性为61%,阴性百分比一致性为79%。
- 血浆cobas检测与二代测序比较的阳性和阴性百分比一致性均达90%以上。
- 组织和血浆检测均T790M阳性的可评估患者中,奥希替尼客观缓解率为64%(95%CI 57-70)。
关键数值与推荐
- 血浆cobas检测与组织检测检测T790M的阳性百分比一致性为61%,阴性百分比一致性为79%。
- 血浆cobas检测与二代测序比较的阳性和阴性百分比一致性均达90%以上。
- 组织和血浆均T790M阳性的可评估患者中,奥希替尼客观缓解率为64%(95%CI 57-70)。
临床怎么用
- 血浆检测阴性的患者在可行时应进行组织检测,以降低血浆假阴性结果风险。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Tumor biopsies for detecting EGFR mutations in advanced NSCLC are invasive, costly, and not always feasible for patients with late-stage disease. The clinical utility of the cobas EGFR Mutation Test v2 (Roche Molecular Systems, Inc., Pleasanton, CA) with plasma samples from patients with NSCLC at disease progression after previous EGFR tyrosine kinase inhibitor therapy was investigated to determine eligibility for osimertinib treatment. METHODS: Matched tumor tissue and plasma samples from patients screened for the AURA extension and AURA2 phase II studies were tested for EGFR mutations by using tissue- and plasma-based cobas EGFR mutation tests. Plasma test performance was assessed by using the cobas tissue test and a next-generation sequencing method (MiSeq [Illumina Inc., San Diego, CA]) as references. The objective response rate, measured by blinded independent central review, was assessed in patients receiving osimertinib with a plasma T790M mutation-positive status. RESULTS: During screening, 551 patients provided matched tumor tissue and plasma samples. Pooled analysis of the positive and negative percent agreements between the cobas plasma and tissue tests for detection of T790M mutation were 61% and 79%, respectively. Comparing cobas plasma test with next-generation sequencing demonstrated positive and negative percent agreements of 90% or higher. The objective response rate was 64% (95% confidence interval: 57-70) in T790M mutation-positive patients by both cobas tissue and plasma tests (evaluable for response). CONCLUSIONS: The cobas plasma test detected the T790M mutation in 61% of tumor tissue T790M mutation-positive patients. To mitigate the risk of false-negative plasma results, patients with a negative plasma result should undergo a tissue test where feasible.
引用
- Jenkins S, Yang JC, Ramalingam SS, et al. Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2017. PMID: 28428148. doi:10.1016/j.jtho.2017.04.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。